Summary

Eligibility
for people ages 12 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around

Description

Summary

The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.

Official Title

RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors

Details

This is a Phase 2/3, randomized study in subjects with progressive desmoid tumors consisting of 2 parts. Phase2/Part A is an open-label, dose regimen finding study; Phase3/Part B is a double blind, placebo-controlled study and Open Label Extension utilizing the dose regimen selected in Phase2/Part A.

Keywords

Desmoid, Desmoid Tumor, RINGSIDE, Aggressive Fibromatosis, Open Label Extension

Eligibility

Locations

  • University of California at Los Angeles Hematology/Oncology
    Santa Monica California 90404 United States
  • Sarcoma Oncology Research Center
    Santa Monica California 90403 United States
  • City of Hope
    Duarte California 91010 United States
  • Stanford University Medical Center
    Stanford California 94305 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Immunome, Inc.
ID
NCT04871282
Phase
Phase 2/3 Desmoid Tumor Research Study
Study Type
Interventional
Participants
Expecting 192 study participants
Last Updated